[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"head-neck-cancer-squamous-cell-metastatic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:head-neck-cancer-squamous-cell-metastatic":35},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100661421","phase-1-a-study-of-225acac-aky-2519-in-patients-with-b7-h3-expressing-solid-tumors-100661421",false,"NCT07887971","A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors","BActinium-2: A Phase 1b, 2 Part, Multicenter, Open Label Study to Evaluate the Safety and Efficacy of Intravenous Administration of a B7-H3 Radiopharmaceutical ([225Ac]Ac AKY 2519) in Participants With B7-H3 Imaging Positive Solid Tumors","BActinium-2","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Histologic or cytologic confirmation of locally advanced or metastatic NSCLC, ES-SCLC, HNSCC, ESCC, CRC or prostatic adenocarcinoma\n* Radiologic confirmation on CT of at least one measurable tumor lesion per RECIST v1.1\n* ECOG Performance Status of 0 or 1\n* Adequate end-organ function\n* Ability to give informed consent and comply with study requirements\n* Patients with CNS metastases are eligible if they have received therapy and are neurologically stable, asymptomatic and not receiving corticosteroids\n\nExclusion Criteria:\n\n* Prior treatment with a B7-H3 targeted therapy\n* Prior treatment with a targeted radiotherapy\n* Received an investigational agent within the previous 28 days\n* Prior treatment with a cytotoxic chemotherapy, targeted therapy, biologic agent, immunotherapy or external-beam radiotherapy within the previous 28 days\n* Impaired cardiac function or clinically significant cardiac disease\n* Concurrent serious medical condition that would impair study participation or impact the assessment of treatment related toxicity","ALL","18 Years",{"count":20,"type":21},152,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This is a Phase 1b, 2-part, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of \\[64Cu\\]Cu-AKY-2519 and\u002For \\[225Ac\\]Ac-AKY-2519, as well as the preliminary anti-tumor activity of \\[225Ac\\]Ac-AKY-2519 in participants with B7-H3 imaging positive solid tumors.",[27,28,29,30,31,32,33,34,35,36,37,38],"NSCLC","NSCLC (Advanced Non-small Cell Lung Cancer)","ES-SCLC","Small Cell Lung Cancer Extensive Stage","B7H3","Prostate Cancer","HNSCC","mCRPC (Metastatic Castration-resistant Prostate Cancer)","Head Neck Cancer Squamous Cell Metastatic","ESCC or Esophageal Adenosquamous Carcinoma","CRC","CRC (Colorectal Cancer)","RECRUITING","2026-10-30",{"date":42,"type":43},"2026-11-02","ACTUAL",{"date":45,"type":21},"2026-11",{"date":47,"type":21},"2033-12",{"name":49,"class":50},"Aktis Oncology, Inc.","INDUSTRY",2]